The impending sale of cardiovascular-device maker Guidant Corp. has been one wild ride for merger arbitrageurs. When Johnson & Johnson announced in December 2004 that it had agreed to buy Guidant for $76 a share in cash and stock, the arbs piled into the $25.4
